Billions of dollars of debt incoming as Allergan shareholders agree takeover
Allergan shareholders have waved through its acquisition by rival drug company AbbVie, clearing a major hurdle on the way to billions of dollars of loans and an expected $30bn of bond issuance.
Votes representing around 68.6% of outstanding shares in US pharmaceuticals company Allergan were cast at an extraordinary general meeting this week, with the overwhelming majority of those — more than 99% — in favour of the acquisition.
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com